The Annual General Meeting of PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Wednesday, June 10, 2026.
All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.
|
Resolutions |
For |
% |
Against |
% |
Withheld |
Total votes cast |
|
001. To approve the Company’s Annual Report and Accounts for year ended 31 December 2025 |
148,986,114 |
99.97 |
46,392 |
0.03 |
10,803 |
149,032,506 |
|
002. To approve the Directors’ Remuneration Report |
142,375,459 |
95.84 |
6,172,764 |
4.16 |
495,086 |
148,548,223 |
|
003. To re-elect Ms. Sharon Barber-Lui as a Director |
143,421,622 |
96.23 |
5,617,352 |
3.77 |
4,335 |
149,038,974 |
|
004. To re-elect Dr. Michele Holcomb as a Director |
148,415,257 |
99.58 |
622,164 |
0.42 |
5,888 |
149,037,421 |
|
005. To re-elect Dr. John LaMattina as a Director |
139,575,205 |
93.65 |
9,462,210 |
6.35 |
5,894 |
149,037,415 |
|
006. To re-elect Dr. Robert Langer as a Director |
142,363,975 |
95.76 |
6,298,309 |
4.24 |
381,025 |
148,662,284 |
|
007. To elect Mr. Robert Lyne as a Director |
148,496,575 |
99.64 |
539,340 |
0.36 |
7,394 |
149,035,915 |
|
008. To re-elect Ms. Kiran Mazumdar-Shaw as a Director |
122,266,593 |
82.04 |
26,769,322 |
17.96 |
7,394 |
149,035,915 |
|
009. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company |
148,776,133 |
99.83 |
257,001 |
0.17 |
10,175 |
149,033,134 |
|
010. To authorize the Audit Committee to determine the Auditors’ remuneration |
148,750,724 |
99.81 |
286,702 |
0.19 |
5,883 |
149,037,426 |
|
011. To authorize the allotment of shares |
147,843,913 |
99.61 |
578,544 |
0.39 |
620,852 |
148,422,457 |
|
012. To disapply pre-emption rights |
147,589,781 |
99.39 |
905,323 |
0.61 |
548,205 |
148,495,104 |
|
013. To further disapply pre-emption rights for acquisitions and specified capital investments. |
146,398,006 |
98.59 |
2,096,790 |
1.41 |
548,513 |
148,494,796 |
|
014. To authorize market purchase of own shares |
148,852,410 |
99.90 |
155,201 |
0.10 |
35,698 |
149,007,611 |
|
015. To authorize general meetings to be called on not less than 14 clear days’ notice |
148,679,278 |
99.76 |
360,501 |
0.24 |
3,530 |
149,039,779 |
Notes:
- A vote “Withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.
- As at June 10, 2026, the number of outstanding shares in the Company was 243,418,190 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
- The full text of the resolutions may be found in the Notice of the Annual General Meeting, copies of which are available on both the Company’s website https://investors.puretechhealth.com/financials-filings/reports and on the National Storage Mechanism.
About PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260610755620/en/
Media gallery
